On behalf of the Organizing Committee and the Congress’ Co-Chairpersons we cordially invite you to join and contribute to the success of the 19th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) 2014 on February 20 – 23, 2014 in Macau, China.
COGI Macau Congress is a continuation of the success of previous editions of the COGI Congress held in the Asia Pacific region in Shanghai, Beijing and Hainan which attracted more than 800 participants in each of the editions.
COGI Macau is dedicated to the three main stream of our field — Infertility, Gynecology and Perinatology — and aims to offer professionals in the field a multidisciplinary platform to learn more about women’s health, gynecological oncology, clinical research and new discoveries.
The aim of the COGI Congresses in general is to increase the ability to discuss controversial topics with an emphasis on clinical solutions in cases where no agreed-upon answers or consensus exist. This provides clinicians with an insight and a take-home message that ameliorates treatment in the most difficult situations and enables the exchange of ideas and information among members of various countries.
- Optimizing Art Results: Large differences exist amoung physicians and programs in the degree and level of applications of technologies as well as applying the most effective stimulation protocol to achieve high success rate in IVF. The IBSA Educational Workshop will host distinguished experts discussing optimization of IVF results.
- In Vitro Maturation (IVM): Clinical relevance of CGH arrays Vs. FISH in embryo screening; IVM: Ovarian tissue freezing and IVM for newly-diagnosed cancer patients
- Luteal Phase Support in Infertility: the controversy around luteal phase support – when should we support, with what and for how long – continues. While there is no doubt of the need to support the luteal phase with progestogens in Infertility treatments, the question remains: for how long? The role of progestogens in recurrent miscarriage is even more complex and is based on expert opinion rather than on level 1 proofThe controversy around luteal phase support – when should we support, with what and for how long – continues. While there is no doubt of the need to support the luteal phase with progestogens in Infertility treatments, the question remains: for how long? The role of progestogens in recurrent miscarriage is even more complex and is based on expert opinion rather than on level 1 proof.
- Decreased Ovarian Reserve (DOR): DOR is a frustrating condition which is associated with lower success rate and very little variation of the response to treatmentDOR is a frustrating condition which is associated with lower success rate and very little variation of the response to treatment
- Fertility Preservation: Cryopreservation and reimplantation of ovarian tissue: Who are the candidates? Results and techniques
- Improving Implantation Rate: Should we be doing all our embryo transfers under ultrasound guidance?
- Ovarian Stimulation (by ISMAAR): It seems odd, but simple questions such as the intensity of stimulation or no stimulation for IVF are still controversial
- Repeated Implantation Failure: Debate: Tthrombophilia/autoinmune treatments improve IVF outcome; How to treat repeated implantation failure? Which progestagen? When and what dose so as to optimise luteal support in IVF/ICSI cycles
- Treatments of PCOS Patients: The controversy over the management of Polycystic Ovarian Syndrome(PCOS) continues. The debate here is on the best way in which to achieve a pregnancy in PCOS patients while minimizing risks. Mild stimulation IVF,IVM, ovarian drilling or GnRH to trigger ovulation: what direction, if any, is preferable? Different points of view – any winner?
- Fetal Medicine: Prenatal diagnosis on cell-free DNA, as a non-invasive method of screening for chromosomal aneuploidy is now ready for use in high risk cases mainly. The possibility to detect point mutation expands the indications. Sensitivity, specificity and the narrow window to its application remains a concern.
- Preeclampsia – Angiogenic Factors and their Implications in Patient Management: A major development was achieved in recent years in identifying various markers and tools for predicting the hypertensive disorders weeks before the onset of preeclampsia resulting in systemic endothelial dysfunction, hypertension, proteinuria, and the other systemic manifestations of preeclampsia. However, medicine is still short of offering an effective prevention plan. The question is do we lose more by not knowing?
- Premature Labor: Preterm birth is responsible to major neonatal morbidity and mortality; can we predict and prevent it?
- Recurrent Pregnancy Loss: LMWH and progesterone to prevent recurrent pregnancy loss; Pregnancy Loss: What do we know & what can we do
- High Risk Delivery: Twins and breeches may be delivered vaginally; Debate: Induction of Labor increases caesarean section rate; Debate: Caesarean section for dystocia can be decreased
- Late Preterm Labors: Late preterm delivery is often associated with multiple pregnancies.
- Diabetes in Pregnancy: Should we tighten the glucose control in gestational diabetic women? Oral anti-diabetic drugs, are they really safe? Debate: Should we change the OGTT thresholds for diagnosing gestational diabetes
- Caesarean Section (CS): The ever increasing CS rate remains a focus of debate, what affects it? Should we strive to decrease?
- Multiple Pregnancies: Multiple pregnancy continue to challenge the obstetricians skills
- Monitoring: What is the best way of monitoring fetal wellbeing on the labor ward (fetal blood sampling vs. STAN); US in the delivery room; Intrapartum fetal monitoring is a risky business for both fetus and doctor; It is no use to further improve assessment of the early IUGR fetus; prevention that is the only issue of importance; “Does Technology Increase the Rate of Prematurity?”
- Intrauterine Growth Restriction (IUGR): IUGR-Using doppler or not? Feasibility of preventing cerebral palsy with magnesium sulfate; Ultrasonography; Management in birth route of IUGR; Office ultrasound — Used by many understood by few
Serono Symposia International Foundation will submit the main congress program of the 19th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) on January 23 – 26, 2014 in Macau, China, for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME).
For the Italian participants
This program of the 19th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) on January 23 – 26, 2014, Macau, China, will be submitted for CME accreditation from the Italian Ministry of Health.
The CME accreditation is valid for the main congress program only and does not cover the company-sponsored symposia.
ISO 9001 Certification
Serono Symposia International Foundation has received the ISO 9001 Certification of Quality Management Systems. This Quality certification requires all participants to fill in a scientific questionnaire and to evaluate the overall quality of the event. Questionnaires will be distributed onsite during the congress.
CME for USA participants
UEMS/EACCME CME credit recognition
The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS). Under the terms of this agreement, the AMA will convert CME credit certified by the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, to AMA PRA Category 1 Credit™. Physicians (MDs, DOs or equivalent international degree) may have their EACCME credit converted to AMA PRA Category 1 Credit™ by applying to the AMA.